Nandrolone
Also known as: Deca-Durabolin, Deca, Nandrolone Decanoate, NPP, Nandrolone Phenylpropionate
Anabolic-Androgenic Steroid | Joint & Collagen Support
Overview
Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP).
Key benefits
- Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
- Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
- Increased bone mineral density through direct osteoblast stimulation
- Improved nitrogen retention and protein synthesis for accelerated recovery
- Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
- Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
- Clinically demonstrated efficacy in treating anemia of chronic renal failure
- Potential neuroprotective properties observed in preclinical research
Mechanism of action
Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1. A key distinguishing feature of nandrolone is its interaction with 5-alpha reductase: unlike testosterone, which is converted to the more potent androgen dihydrotestosterone (DHT), nandrolone is reduced to dihydronandrolone (DHN), a weaker androgen. This results in lower androgenic activity in tissues rich in 5-alpha reductase (skin, prostate, hair follicles). Nandrolone also stimulates collagen synthesis and bone mineral content through direct effects on osteoblasts and fibroblasts, contributing to its well-documented benefits for joint and connective tissue health. It exhibits moderate progestogenic activity, binding to the progesterone receptor at approximately 20% the affinity of progesterone, which can influence prolactin levels and contribute to progesterone-related side effects. Nandrolone aromatizes to estradiol at roughly 20% the rate of testosterone, resulting in lower but not absent estrogenic activity.
Molecular data
- Type
- 19-nortestosterone steroid (C18H26O2)
- Half-life
- ~6-12 days (decanoate)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Hematological
Musculoskeletal / Connective Tissue
Body Composition
Recovery / Healing
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 50-100 mg/week | 1x per week (decanoate) | — |
| — | 100-200 mg/week | 1x per week (decanoate) | — |
| — | 200-400 mg/week | 1x per week (decanoate) or split into 2 injections | — |
| — | 200-350 mg/week | Every other day or 3x per week | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
- Water retention and bloating (less than testosterone at equianabolic doses)
- Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
- Increased appetite and weight gain
- Mild acne and oily skin (less pronounced than testosterone)
- Elevated hematocrit and hemoglobin (erythrocytosis)
- Injection site pain or discomfort
- Mild mood changes (some users report increased emotional sensitivity)
Rare side effects
- Gynecomastia from progesterone-mediated prolactin elevation (distinct from estrogen-mediated gyno)
- Elevated prolactin causing lactation, mood disturbance, or sexual dysfunction
- Significant HDL cholesterol suppression and adverse lipid changes
- Left ventricular hypertrophy with prolonged supraphysiological use
- Hepatotoxicity (very rare with injectable nandrolone, not a 17-alpha-alkylated steroid)
- Virilization in women (deepening voice, hirsutism, clitoral enlargement) at higher doses
- Insomnia and night sweats at higher doses
- Depression or anxiety, particularly during discontinuation
Contraindications
- Prostate cancer (active or history of hormone-sensitive prostate cancer)
- Breast cancer in males or females
- Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
- Nephrosis or the nephrotic phase of nephritis
- Severe hepatic impairment
- Hypercalcemia
- Known hypersensitivity to nandrolone or any formulation components
- Polycythemia (hematocrit above 54% at baseline)
- Uncontrolled heart failure or severe cardiovascular disease
Monitoring
- Total and free testosterone: baseline and every 6-8 weeks during use
- Estradiol (sensitive assay): at each blood draw, especially when co-administered with testosterone
- Prolactin: baseline, 4-6 weeks after starting, and as needed if symptoms arise
- Complete blood count with hematocrit: baseline, 6-8 weeks, then every 3 months
- Comprehensive metabolic panel and lipid panel: baseline and every 8-12 weeks
- Liver function tests: baseline and periodic monitoring
- PSA (prostate-specific antigen): baseline and every 6 months for men over 40
- Progesterone: optional baseline and periodic check if progestogenic symptoms appear
- Blood pressure: regular monitoring throughout use
References
Primary literature and clinical-trial data informing this entry.